Similarly, Weber et al. evaluated the potential role MALAT1 as a blood-based biomarker for NSCLC, finding a sensitivity of 56% and specificity of 96% in distinguishing cancer patients and cancer-free controls. The gene discussed is MALAT1; the disease is cancer.